Anticancer agent 210_product_DataBase

Bioactivity	Anticancer agent 210 (Compound 7a) is a Gefitinib (HY-50895) derivative. Anticancer agent 210 inhibits proliferation, migration and colony formation of cancer cells. Anticancer agent 210 induces apoptosis in cells H1299[1].
Invitro	Anticancer agent 210 (0-32 μM，48 h) 抑制肺癌细胞 NCI-H1299，A549 和 NCI-H1437增殖，IC50 分别为 3.94，3.16 和 1.84 μM[1]。Anticancer agent 210 (2-16 μM，48 h) 对正常肝细胞 L02 表现出轻微的细胞毒性，IC50 为 18.87 μM，L02 细胞存活率 >60%[1]。Anticancer agent 210 (4-16 μM，48 h) 通过 Bcl-2/caspase3/PARP 通路诱导非小细胞肺癌 (NSCLC) 细胞凋亡，通过抑制 MMP9 蛋白表达抑制 NSCLC 细胞迁移[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Anticancer agent 210 相关抗体: Cell Proliferation Assay[1] Cell Line:
In Vivo	Anticancer agent 210 (400 mg/kg，口服，单剂量) 对 Kunming 小鼠没有表现出明显的毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Formula	C31H31BrFN7O3
Molar Mass	648.53
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Gao E, et al., Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation. Sci Rep. 2024 Apr 22;14(1):9223.

PeptideDB